BioNTech (BNTX) Expected to Announce Earnings on Monday

BioNTech (NASDAQ:BNTX) is expected to post its Q4 2025 results before the market opens on Monday, March 9th. Analysts expect BioNTech to post earnings of ($0.57) per share and revenue of $941.9940 million for the quarter. Individuals are encouraged to explore the company’s upcoming Q4 2025 earning overview page for the latest details on the call scheduled for Tuesday, March 10, 2026 at 8:00 AM ET.

BioNTech Trading Up 1.3%

Shares of BNTX stock opened at $110.23 on Monday. The company has a market capitalization of $24.82 billion, a price-to-earnings ratio of -41.91 and a beta of 1.51. The company has a current ratio of 7.12, a quick ratio of 7.02 and a debt-to-equity ratio of 0.01. The firm has a 50-day moving average price of $105.95 and a 200 day moving average price of $103.41. BioNTech has a twelve month low of $81.20 and a twelve month high of $124.00.

Institutional Trading of BioNTech

A number of institutional investors and hedge funds have recently made changes to their positions in the company. EFG International AG purchased a new position in shares of BioNTech in the 4th quarter worth $29,000. Caitong International Asset Management Co. Ltd grew its position in BioNTech by 520.0% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 310 shares of the company’s stock valued at $30,000 after acquiring an additional 260 shares during the period. Tower Research Capital LLC TRC grew its position in BioNTech by 118.2% during the second quarter. Tower Research Capital LLC TRC now owns 563 shares of the company’s stock valued at $60,000 after acquiring an additional 305 shares during the period. NewEdge Advisors LLC acquired a new stake in BioNTech during the first quarter worth about $167,000. Finally, Osaic Holdings Inc. raised its holdings in shares of BioNTech by 27.3% in the 2nd quarter. Osaic Holdings Inc. now owns 1,949 shares of the company’s stock worth $208,000 after purchasing an additional 418 shares during the period. 15.52% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of equities analysts have recently weighed in on BNTX shares. HC Wainwright reissued a “buy” rating and issued a $140.00 price objective on shares of BioNTech in a research report on Thursday, December 11th. UBS Group raised shares of BioNTech to a “hold” rating in a research note on Thursday, December 4th. TD Cowen reiterated a “hold” rating on shares of BioNTech in a report on Monday, November 3rd. Weiss Ratings restated a “sell (d-)” rating on shares of BioNTech in a report on Friday, January 9th. Finally, Berenberg Bank reaffirmed a “buy” rating on shares of BioNTech in a research report on Friday, January 23rd. Eleven analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $140.10.

About BioNTech

BioNTech SE (NASDAQ: BNTX) is a Germany-based biotechnology company that develops next-generation immunotherapies and vaccines, with a primary focus on messenger RNA (mRNA) technology. Founded in 2008 and headquartered in Mainz, BioNTech advances a platform approach to design and manufacture therapeutics across oncology, infectious diseases and other high unmet-need areas. The company is publicly traded on the NASDAQ exchange and became widely known for its rapid development and global deployment of an mRNA-based COVID-19 vaccine in collaboration with Pfizer.

BioNTech’s core activities include discovery research, clinical development and manufacturing of mRNA-based medicines, personalized cancer immunotherapies, engineered cell therapies, and antibody- and protein-based therapeutics.